DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1438 stomatitis, chills, abdominal pain, and edema. Laboratory abnormalities
noted in 12-26% of patients with AIDS include leukopenia and
occasional agranulocytosis, thrombocytopenia, proteinuria, and elevations
of plasma creatinine, transaminases, and bilirubin, which are
reversible. Unexpected findings in patients with AIDS include adrenal
insufficiency and vortex keratopathy.
Precautions and Contraindications. Patients receiving suramin should
be followed closely. Therapy should not be continued in patients
who show intolerance to initial doses, and the drug should be
employed with great caution in individuals with renal insufficiency.
Moderate albuminuria is common during control of the acute phase,
but persisting, heavy albuminuria calls for caution as well as modification
of the treatment schedule. If casts appear, treatment with
suramin should be discontinued. The occurrence of palmar-plantar
hyperesthesia may presage peripheral neuritis.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
BIBLIOGRAPHY
Abboud P, Lemee V, Gargala G, et al. Successful treatment of
metronidazole- and albendazole-resistant giardiasis with nitazoxanide
in a patient with acquired immunodeficiency syndrome.
Clin Infect Dis, 2001, 32:1792–1794.
Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity
of nitazoxanide and related compounds against isolates of
Giardia intestinalis, Entamoeba histolytica, and Trichomonas
vaginalis. J Antimicrob Chemother, 2002, 49:103–111.
Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization
of drug targets: The TDR Targets database. Nat Rev
Drug Discov, 2008, 7:900–907.
Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and
control of leishmaniasis. Adv Parasitol, 2006, 61:223–274.
Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on
morbidity and mortality in Zambian children with cryptosporidiosis:
A randomized, controlled trial. Lancet, 2002,
360:1375–1380.
Bacchi CJ, Nathan HC, Hunter SH, et al. Polyamine metabolism:
A potential therapeutic target in trypanosomes. Science,
1980, 210:332–334.
Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus
eflornithine for treating late-stage Gambian trypanosomiasis
in the Republic of the Congo. Bull World Health Organ,
2006a, 84:783–791.
Balasegaram M, Harris S, Checchi F, et al. Treatment outcomes
and risk factors for relapse in patients with early-stage human
African trypanosomiasis (HAT) in the Republic of the Congo.
Bull World Health Organ, 2006b, 84:777–782.
Balasegaram M, Young H, Chappuis F, et al. Effectiveness of
melarsoprol and eflornithine as first-line regimens for gambiense
sleeping sickness in nine Médecins Sans Frontières programmes.
Trans R Soc Trop Med Hyg, 2009, 103:280–290.
Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African
trypanosomiasis: Pharmacological re-engagement with a neglected
disease. Br J Pharmacol, 2007, 152:1155–1171.
Berman JJ. Treatment of leishmaniasis with miltefosine: 2008
status. Expert Opin Drug Metab Toxicol, 2008, 4:
1209–1216.
Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and
treatment of Chagas disease in the United States: A systematic
review. JAMA, 2007, 298:2171–2181.
Bern C, Montgomery SP, Katz L, et al. Chagas disease and the
US blood supply. Curr Opin Infect Dis, 2008, 21:476–482.
Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine
for the treatment of Indian visceral leishmaniasis. J Infect
Dis, 2007, 196:591–598.
Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients
with second stage human African trypanosomiasis. Acta Trop,
2006, 97:55–64.
Bronner U, Gustafsson LL, Doua F, et al. Pharmacokinetics and
adverse reactions after a single dose of pentamidine in patients
with Trypanosoma gambiense sleeping sickness. Br J Clin
Pharmacol, 1995, 39:289–295.
Brun R, Schumacher R, Schmid C, et al. The phenomenon of
treatment failures in human African trypanosomiasis. Trop
Med Int Health, 2001, 6:906–914.
Burri C, Brun R. Eflornithine for the treatment of human African
trypanosomiasis. Parasitol Res, 2003, 90(suppl):49–52.
Burri C, Keiser J. Pharmacokinetic investigations in patients
from northern Angola refractory to melarsoprol treatment.
Trop Med Int Health, 2001, 6:412–420.
Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure
drives conversion to a stable and protective CD8+ T central
memory response in chronic Chagas disease. Nat Med, 2008,
14:542–550.
Casero RA Jr, Marton LJ. Targeting polyamine metabolism and
function in cancer and other hyperproliferative diseases. Nat
Rev Drug Discov, 2007, 6:373–390.
Chappuis F. Melarsoprol-free drug combinations for secondstage
Gambian sleeping sickness: The way to go. Clin Infect
Dis, 2007, 45:1443–1445.
Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis:
What are the needs for diagnosis, treatment and control? Nat
Rev Microbiol, 2007, 5:873–882.
Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer
than melarsoprol for the treatment of second-stage
Trypanosoma brucei gambiense human African trypanosomiasis.
Clin Infect Dis, 2005, 41:748–751.
Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-
Johnson syndrome/toxic epidermal necrolysis associated with
mebendazole and metronidazole use among Filipino laborers
in Taiwan. Am J Public Health, 2003, 93:489–492.
Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony
during treatment of visceral leishmaniasis with sodium
stibogluconate or meglumine antimonate. Trans R Soc Trop
Med Hyg, 1988, 82:69–72.
Cooley G, Etheridge RD, Boehlke C, et al. High throughput
selection of effective serodiagnostics for Trypanosoma cruzi
infection. PLoS Negl Trop Dis, 2008, 2:e316.
Croft SL. Neglected diseases: Progress in drug development.
Curr Opin Invest Drugs, 2007, 8:103–104.
Croft SL. Kinetoplastida: New therapeutic strategies. Parasite,
2008, 15:522–527.
Croft SL, Coombs GH. Leishmaniasis: Current chemotherapy
and recent advances in the search for novel drugs. Trends
Parasitol, 2003, 19:502–508.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis.
Clin Microbiol Rev, 2006, 19:111–126.
de Koning HP. Ever-increasing complexities of diamidine and
arsenical cross resistance in African trypanosomes. Trends
Parasitol, 2008, 24:345–349.